TRDA - Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? | Benzinga
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in Duchenne Muscular Dystrophy.
The FDA previously notified Entrada that the Investigational New Drug (IND) application for the Phase 1 clinical trial of ENTR-601-44 had been placed on clinical hold.
Despite providing additional information to the FDA, the company was informed that the Agency declined to lift the clinical hold.
The company said the information submitted to the FDA supported initiating the Phase 1 clinical ...